Test Overview
Clinical Utility
sFlt-1/PlGF ratio is intended for use to help rule-out preeclampsia and predict short-term risk of developing preeclampsia in women between 20 weeks and 36 weeks + 6 days gestation.
Method
Electrochemiluminescent immunoassay (ECLIA)
Result Included
sFlt-1; PLGF; sFlt-1/PLGF Ratio
Aliases/Synonyms
Soluble fms-like tyrosine kinase-1; Soluble fms like tyrosine kinase 1; Placental Growth Factor; PGF; Preeclampsia; Pre-eclampsia
Specimen
Specimen Type
SerumImportant: You must contact ICL prior to specimen collection to get approval for urgent service. ICL will require delivery details for approval. (416) 422-3000 x 300 or by email so that ICL can anticipate delivery and arrange urgent transfer of the specimen for testing. Currently, this service is available Monday to Friday during regular hours.
Containers
Collection Containers
Gold top (SST); Red top (no additive)
Volume
Sample Volume
1 mL
Minimum Volume
0.5mL
Collection & Handling
Handling Information
Separate serum and send sample cold or frozen.
Important: You must contact ICL prior to specimen collection to get approval for urgent service. ICL will require delivery details for approval. (416) 422-3000 x 300 or by email so that ICL can anticipate delivery and arrange urgent transfer of the specimen for testing.
Stability
| Refrigerated | Frozen |
|---|---|
| 3 days | 6 months |
Performance & Interpretation
Turnaround Time
1 day
Results
-
Soluble fms-like tyrosine kinase-1 (sFlt-1)ng/L
-
Placental Growth Factor (PLGF)ng/L
-
sFlt-1PLGF ratioRatioRisk of preeclampsia within 7 days:
≤ 38: Considered low risk
> 38 and ≤ 85: Considered moderate risk
> 85: Considered high risk
Referral Location
Canada
Interface & Setup
HL7 Interface Codes
| Order Code | Result Name | Result Codes | Units |
|---|---|---|---|
| SFPLB S | sFLT-1 | 64049 | ng/L |
| PLGF | 64050 | ng/L | |
| sFlt-1/PLGF Ratio | 64051 |
Test Version
Last Updated
2023-11-30